Showing 4541-4550 of 6411 results for "".
- Study: Newer Biologics Do Not Increase MACE/VTE Risk in PsO/PsAhttps://practicaldermatology.com/news/Study-Newer-Biologics-Do-Not-Increase-MACE-VTE-Risk-PsO-PsA/2471065/A new emulated target trial analysis found no significant risk differences in major adverse cardiovascular events (MACE) or venous thromboembolic events (VTE) in patients with psoriasis or psoriatic arthritis treated with IL-17, IL-12/23, or IL-23 inhibitors vs those treated with TNF inhibitors.<
- Biologic Therapy in Psoriasis: Secukinumab and Ustekinumab Lead in Retentionhttps://practicaldermatology.com/news/biologic-therapy-in-psoriasis-secukinumab-and-ustekinumab-lead-in-retention/2471042/Switching patterns of biologics in psoriasis treatment revealed influences of gender and psoriatic arthritis (PsA), according to new research. The retrospective study from the nationwide digital prescription database of Greece has shed light on biologic treatment trends for psoriasis betwe
- Study: Safety Signals Emerge for IL-23 and IL-12/23 Inhibitors in Psoriasis Treatmenthttps://practicaldermatology.com/news/safety-signals-emerge-for-il-23-and-il-1223-inhibitors-in-psoriasis-treatment/2470971/A new analysis of psoriasis patients indicates an emergence of new safety signals associated with interleukin-23 (IL-23) inhibitors and the IL-12/23 inhibitor ustekinumab. Researchers on the study analyzed 41.4 million adverse event (AE) reports from the FDA Adverse Event Reporting System
- Study: Higher Isotretinoin Doses Reduce Acne Relapse Riskhttps://practicaldermatology.com/news/study-higher-isotretinoin-doses-reduce-acne-relapse-risk/2470951/Results from a new cohort study show higher cumulative isotretinoin dosages are associated with lower rates of acne relapse and retreatment, and that daily dosing does not influence these outcomes for patients on conventional or high cumulative doses. Authors on the study analyzed data fro
- GHG Audit Shows Key Emission Sources in Dermatology Practicehttps://practicaldermatology.com/news/ghg-audit-shows-key-emission-sources-dermatology-practice/2470894/A new study has identified scope 3 emissions, particularly purchased goods and services, as the largest contributor to the carbon footprint of an outpatient dermatology clinic, accounting for 51.1% of total greenhouse gas (GHG) emissions. The research, conducted at a University of Pennsylv
- Analysis: FDA Approvals Highlight Disparities in Oncology Outcomes by Ancestryhttps://practicaldermatology.com/news/analysis-fda-approvals-highlight-disparities-oncology-outcomes-ancestry/2470889/Patients of African ancestry remain underrepresented in eligibility for biomarker-driven precision oncology therapies, according to a new study in JAMA Dermatology. The retrospective analysis of 59,433 patients with solid cancers looked at genetic sequencing data from MSK-IMPACT a
- Review Examines Potential of AI Tools for Physician Burnouthttps://practicaldermatology.com/news/streamlining-charting-ai-tools/2470864/Patient documentation tools powered by AI have the potential to alleviate burnout among dermatologists by streamlining administrative tasks, according to a recent review published in the Journal of Drugs in Dermatology. "The prevalence of burnout among United States (US) dermatolo
- Analysis: No Risk Differences in MACE and VTE Among Biologics for Psoriatic Diseasehttps://practicaldermatology.com/news/analysis-no-risk-differences-mace-and-vte-among-biologics-psoriatic-disease/2470809/A recent cohort analysis revealed no significant differences in the risks of major adverse cardiovascular events (MACE) and venous thromboembolic events (VTE) among biologic-naïve patients with psoriasis or psoriatic arthritis (PsA) treated with different classes of biologics. Researchers
- Neurotrimin Identified as Key Target for Keloid Treatment: Analysishttps://practicaldermatology.com/news/neurotrimin-identified-key-target-keloid-treatment-analysis/2470778/Researchers for a new genetic study have identified seven proteins as potential drug targets for the treatment of keloids, with neurotrimin (NTM) emerging as a particularly significant finding. Publishing in the Journal of Investigative Dermatology, the study design employed a two-sample M
- Study: Ongoing Inequities in Dermatology Productivity Metricshttps://practicaldermatology.com/news/study-ongoing-inequities-dermatology-productivity-metrics/2470777/A new study in JAMA Dermatology revealed that while the 2021 Medicare physician fee schedule updates reduced inequities in work relative value units (wRVUs) for outpatient dermatology visits, significant disparities based on patient demographics persist. Analyzing data from 89,656